See All Slides - tctmd.com

Slides

Presentation TCT 2012

Overview 1: Biological Therapies for Heart Failure: Clinical Perspectives and Progress

Presenter: Timothy Henry

October 23, 2012

Presentation TCT 2012

Debate III. Is Long-term Patency Following Tibial Intervention for Critical Limb Ischemia Necessary? Pro!

Presenter: Thomas Zeller

October 23, 2012

Presentation TCT 2012

Introduction(13)

Presenter: Ralph Verdino

October 23, 2012

Presentation TCT 2012

Should VH-IVUS Be Used as a Clinical Tool to Detect and Treat Vulnerable Plaque TODAY: From PROSPECT to VIVA

Presenter: Patrick Calvert

October 23, 2012

Presentation TCT 2012

Most Diseases Are Systemic: It's the Focal Manifestations that Count!

Presenter: James Muller

October 23, 2012

Presentation TCT 2012

What Will We Learn from the EXCEL Trial that We Do Not Already Know?

Presenter: Gregg Stone

October 23, 2012

Presentation TCT 2012

Counterpulsation for Chronic Heart Failure: Sunshine

Presenter: William Abraham

October 23, 2012

Presentation TCT 2012

Lifetech LAA Closure Device: Description and Preclinical Results

Presenter: Yat-Yin Lam

October 23, 2012

Presentation TCT 2012

VESTAsync (MIV Therapeutics) Program Update

Presenter: Ricardo Costa

October 23, 2012

Presentation TCT 2012

TCT-18. Long-term Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve After Deferral of Percutaneous Coronary Intervention

Presenter: Tim van de Hoef

October 23, 2012

Advertisement

Slides

Overview 1: Biological Therapies for Heart Failure: Clinical Perspectives and Progress

Debate III. Is Long-term Patency Following Tibial Intervention for Critical Limb Ischemia Necessary? Pro!

Introduction(13)

Should VH-IVUS Be Used as a Clinical Tool to Detect and Treat Vulnerable Plaque TODAY: From PROSPECT to VIVA

Most Diseases Are Systemic: It's the Focal Manifestations that Count!

What Will We Learn from the EXCEL Trial that We Do Not Already Know?

Counterpulsation for Chronic Heart Failure: Sunshine

Lifetech LAA Closure Device: Description and Preclinical Results

VESTAsync (MIV Therapeutics) Program Update

TCT-18. Long-term Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve After Deferral of Percutaneous Coronary Intervention

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content